Skip to main content
Evidence Snapshot

Blood

CHEMBL613416 TISSUE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:19Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613416
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Blood as ChEMBL target CHEMBL613416. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Blood
TISSUE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL613416
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Blood matters

As of 2026-09-13

Blood is reviewed as Blood; the current evidence base includes 16 approved drugs, 2148 compounds, and 479 assays, with lead potency reaching pChEMBL 10.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 2148 compounds, and 479 assays for this target. The dominant activity type is IC50. CHEMBL5419663 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL5419663 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Blood matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2148
Total Compounds
479
Total Assays
16
Approved Drugs
IC50: 2103.0, KI: 1.0, EC50: 118.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5419663
 10.1 EC50 —
No preferred name
CHEMBL452578
 9.9 IC50 —
No preferred name
CHEMBL462150
 9.9 IC50 —
No preferred name
CHEMBL323312
 9.5 IC50 —
No preferred name
CHEMBL516978
 9.4 IC50 —

Approved Drugs

Structure Compound First Approval
DEUCRAVACITINIB
CHEMBL4435170
 2022
APREMILAST
CHEMBL514800
 2014
ROFLUMILAST
CHEMBL193240
 2010
FLUTICASONE FUROATE
CHEMBL1676
 2007
BUDESONIDE
CHEMBL1370
 1994
FLUTICASONE PROPIONATE
CHEMBL1473
 1990
INDOMETHACIN
CHEMBL6
 1965
DEXAMETHASONE
CHEMBL384467
 1958
PREDNISOLONE
CHEMBL131
 1955
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:19Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613416